---
symbol: "XBI"
name: "SPDR Biotech ETF"
date: 2026-11-17
change_pct: -2.02765589682222
direction: "down"
event_type: "regulatory_legal"
url: "https://perplo.app/why/XBI/2026-11-17"
updated_at: 2026-11-17T14:06:58.919Z
---

# Why SPDR Biotech ETF (XBI) fell 2.03% on November 17, 2026

SPDR Biotech ETF (XBI) fell 2.03% on November 17, 2026 — FDA rejection of a closely watched cancer drug hits biotech.

## What happened

The FDA declined to approve one of biotech's most closely watched cancer drugs, a rejection the FT says is a blow to China's biotech industry because the drug was developed there.

## Why it moved

A high-profile rejection forces the market to lower its approval odds for similar late-stage assets, which compresses multiples across a basket of small and mid-cap biotechs.

## Why it matters

This sits inside a Healthcare & Biotech theme where GLP-1 obesity adoption and a small-cap biotech bid had lifted Lilly and Hims.

## What would break the thesis

If the company secures a clear path to approval through new data or a quick resubmission, the read-through fades and the group can recover.

## Sources

- [The FDA declined to approve one of biotech’s most closely watched cancer drugs](https://www.marketwatch.com/story/the-fda-declined-to-approve-one-of-biotechs-most-closely-watched-cancer-drugs-d7c6a0a3?mod=mw_rss_topstories) — MarketWatch
- [CHINA'S BIOTECH INDUSTRY FACES BLOW AS US REGULATOR REJECTS CANCER DRUG DEVELOPED IN CHINA - FT](https://t.me/marketfeed/1078457) — MarketFeed

---

Trade XBI perpetual futures 24/7 onchain: https://perplo.app/asset/XBI
